Compositions and methods for treatment of prostate carcinoma

A method of inhibiting or delaying the growth of prostate cancer, comprising administering to a subject having prostate cancer a therapeutically effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt thereof:

• wherein:
• R1 is —O—R3 or —NR4R5;
• R2 is selected from the group consisting of hydrogen, halogen, and —O—R3;
• R3 is an optionally substituted aryl, wherein the aryl is optionally substituted with one to five groups independently selected from the group consisting of —OH, —COOH, —NR6R7, halogen, nitro, cyano, C1-6 alkyl, C1-6 alkoxy, C1-6 haloalkoxy, C6-C14 aryloxy, C6-C14 aralkyloxy, C6-C14 aralkyl, —(C═O)—C1-6 alkyl, —(C═O)—O—C1-6 alkyl, —N—(C═O)—C1-6 alkyl, —C1-6 alkyl-N(R6)(R7), —O(C═O)—NH—C1-6 alkyl, and —O(C═O)—NH—C1-6 haloalkyl;
• R4 and R5 are independently selected from the group consisting of hydrogen, —(C═O)—C1-6 alkyl, and an optionally substituted aryl, wherein the aryl is optionally substituted with one to five groups independently selected from the group consisting of C1-6 alkyl, C1-6 alkoxy, C1-6 haloalkoxy, C6-C14 aryloxy, C6-C14 aralkyloxy, C6-C14 aralkyl, —(C═O)—C1-6 alkyl, —SO2N—C(═O)—C1-6 alkyl, and —SO2NH2;
• R6 and R7 are independently selected from hydrogen and an optionally substituted C1-6 alkyl;
• wherein the growth of prostate cancer is inhibited or delayed;
• and, optionally,
• wherein the compound of Formula (I) is administered to the subject in combination with, subsequent to, or concomitantly with, an androgen deprivation therapy.

A method of inhibiting or delaying the growth of prostate cancer, comprising administering to a subject having prostate cancer a therapeutically effective amount of a compound of Formula (III) or a compound having the following chemical structure or a pharmaceutically acceptable salt thereof:

• wherein R11 is selected from the group consisting of C1-6 alkyl, C1-6 haloalkyl, —(C═O)—C1-6 alkyl, and —(C═O)—C1-6haloalkyl;
• wherein the growth of prostate cancer is inhibited or delayed;
• and, optionally,
• wherein the compound of Formula (III) or Formula (F51) is administered to the subject in combination with, subsequent to, or concomitantly with, an androgen deprivation therapy.

A product combination that inhibits prostate cancer in a subject, wherein the product combination comprises a compound of Formula (I), Formula (III), or Formula (F51), or a pharmaceutically acceptable salt thereof, and a hormone therapy agent;

• and
• wherein the compound of Formula (I), Formula (III), and Formula (F51) have the following structures:
• wherein:
• R1 is —O—R3 or —NR4R5;
• R2 is selected from the group consisting of hydrogen, halogen, and —O—R3;
• R3 is an optionally substituted aryl, wherein the aryl is optionally substituted with one to five groups independently selected from the group consisting of —OH, —COOH, —NR6R7, halogen, nitro, cyano, C1-6 alkyl, C1-6 alkoxy, C1-6 haloalkoxy, C6-C14 aryloxy, C6-C14 aralkyloxy, C6-C14 aralkyl, —(C═O)—C1-6 alkyl, —(C═O)—O—C1-6 alkyl, —N—(C═O)—C1-6 alkyl, C1-6 alkyl-N(R6)(R7), —O(C═O)—NH—C1-6 alkyl, and —O(C═O)—NH—C1-6 haloalkyl;
• R4 and R5 can be independently selected from the group consisting of hydrogen, —(C═O)—C1-6 alkyl, and an optionally substituted aryl, wherein the aryl is optionally substituted with one to five groups independently selected from halogen, C1-6 alkyl, C1-6 haloalkyl, C1-6 alkoxy, C1-6 haloalkoxy, C6-C14 aryloxy, C6-C14 aralkyloxy, C6-C14 aralkyl, —(C═O)—C1-6 alkyl, —SO2N—C(═O)—C1-6 alkyl, and —SO2NH2;
• R6 and R7 are independently selected from hydrogen and an optionally substituted C1-6 alkyl;
• and
• R11 is selected from the group consisting of C1-6 alkyl, C1-6 haloalkyl, —(C═O)—C1-6 alkyl, and —(C═O)—C1-6haloalkyl.